APOH (Beta-2-glycoprotein 1) variants and mutations
APOH (also known as Beta-2-glycoprotein 1) is a human protein-coding gene encoding a beta-2-glycoprotein 1 protein. It binds negatively charged phospholipids and participates in coagulation, lipid metabolism, and clearance of apoptotic material. It is also the major antigen recognized by pathogenic antiphospholipid antibodies in antiphospholipid syndrome. This analysis covers 680 APOH variants and mutations. Of these, 80% have computational variant effect predictions. Disease context includes atrial fibrillation, Hypercholesterolemia, and metabolic syndrome. Example APOH variants include M1?, S3Y, and P4L.
Variant analysis overview
- Gene: APOH
- Protein: Beta-2-glycoprotein 1
- UniProt accession: P02749
- Organism: Homo sapiens
- Variants analyzed: 680
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 460 unspecified-consequence records; 1 stop retained variant; 8 stop-gained variants; 83 synonymous variants; 98 missense variants; 21 frameshift variants; 2 splice-region variants; 6 in-frame deletions; 2 in-frame insertions
- Prediction scores: 543 variants have prediction scores (80% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: atrial fibrillation, Hypercholesterolemia, metabolic syndrome, familial lipoprotein lipase deficiency, atrial flutter, alcohol drinking, response to statin, ovarian endometriosis, chronic obstructive pulmonary disease, cardiac arrhythmia, autoimmune disorder of central nervous system, bronchopneumonia.
Protein structure and variant hotspots
- Protein features: 4 domains; 6 post-translational modification sites.
- Structural context: 452 variants have structural context.
- PTM context: 12 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable APOH variants
Examples include M1?, S3Y, P4L, P4S, V5A, L6F, L6H, L6V. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, rs898598847, NCI-TCGA Cosmic COSV5277, MetaLR 0.14, MetaSVM -0.96, Variant assessed as somatic; high impact.
- S3Y (p.Ser3Tyr), NCI-TCGA Cosmic COSV5277, Variant assessed as somatic; moderate impact.
- P4L (p.Pro4Leu), NCI-TCGA Cosmic COSV5277, REVEL 0.07, CADD 14.70, Variant assessed as somatic; moderate impact.
- P4S (p.Pro4Ser), gnomAD rs1405969482
- V5A (p.Val5Ala), rs3826358, UniProt VAR 048316, 1000Genomes rs3826358, ESP rs3826358, REVEL 0.01, CADD 0.02
- L6F (p.Leu6Phe), TOPMed rs1157005765, gnomAD rs1157005765, REVEL 0.09, CADD 14.50
- L6H (p.Leu6His), TOPMed rs2073460603
- L6V (p.Leu6Val), TOPMed rs1157005765, gnomAD rs1157005765, REVEL 0.09, CADD 16.70
- S10* (p.Ser10Ter), ESP rs147357246, ExAC rs147357246, TOPMed rs147357246, gnomAD rs147357246, CADD 33.00, Uncertain significance
- S10L (p.Ser10Leu), ESP rs147357246, ExAC rs147357246, TOPMed rs147357246, gnomAD rs147357246, REVEL 0.04, CADD 11.70, Uncertain significance
- S10W (p.Ser10Trp), ESP rs147357246, ExAC rs147357246, TOPMed rs147357246, gnomAD rs147357246, REVEL 0.12, CADD 20.70, Uncertain significance, not specified
- S11T (p.Ser11Thr), TOPMed rs907406873, gnomAD rs907406873, REVEL 0.05, CADD 5.64
- C14* (p.Cys14Ter), TOPMed rs1270775645, gnomAD rs1270775645, CADD 35.00
- C14S (p.Cys14Ser), gnomAD rs1431608397
- H15L (p.His15Leu), TOPMed rs1223008992, gnomAD rs1223008992, REVEL 0.27, CADD 24.70
- V16F (p.Val16Phe), ExAC rs769892837, TOPMed rs769892837, gnomAD rs769892837, REVEL 0.14, CADD 17.70
- V16I (p.Val16Ile), ExAC rs769892837, TOPMed rs769892837, gnomAD rs769892837, REVEL 0.08, CADD 16.70
- I18T (p.Ile18Thr), ExAC rs778339607, gnomAD rs778339607, REVEL 0.10, CADD 16.10
- A19T (p.Ala19Thr), Ensembl rs1450152076, REVEL 0.20, CADD 22.80
- A19V (p.Ala19Val), TOPMed rs1226137850, gnomAD rs1226137850, REVEL 0.15, CADD 22.40
- R21=, NCI-TCGA Cosmic COSV5277, NCI-TCGA Cosmic COSV9923, Variant assessed as somatic; low impact.
- R21P (p.Arg21Pro), ESP rs149659675, ExAC rs149659675, TOPMed rs149659675, gnomAD rs149659675, REVEL 0.21, CADD 14.50
- R21Q (p.Arg21Gln), rs149659675, NCI-TCGA Cosmic COSV9923, ESP rs149659675, ExAC rs149659675, REVEL 0.10, CADD 18.00, Variant assessed as somatic; moderate impact.
- R21W (p.Arg21Trp), ESP rs200237222, ExAC rs200237222, TOPMed rs200237222, gnomAD rs200237222, REVEL 0.22, CADD 22.80
- K25N (p.Lys25Asn), Ensembl rs867396800
- D27N (p.Asp27Asn), TOPMed rs1471958766, REVEL 0.08, CADD 22.40
- D28E (p.Asp28Glu), ExAC rs755547171, TOPMed rs755547171, gnomAD rs755547171, REVEL 0.13, CADD 0.00
- D28G (p.Asp28Gly), TOPMed rs1156403474, gnomAD rs1156403474, REVEL 0.16, CADD 9.85
- D28N (p.Asp28Asn), Ensembl rs868680805
- P30S (p.Pro30Ser), TOPMed rs1433596837, gnomAD rs1433596837, REVEL 0.22, CADD 18.60
- P30T (p.Pro30Thr), TOPMed rs1433596837, gnomAD rs1433596837, REVEL 0.24, CADD 18.10
- S32A (p.Ser32Ala), 1000Genomes rs566373863, ExAC rs566373863, gnomAD rs566373863, REVEL 0.13, CADD 7.33
- V34A (p.Val34Ala), TOPMed rs1567743212, gnomAD rs1567743212, REVEL 0.40, CADD 21.30
- V34E (p.Val34Glu), TOPMed rs1567743212, gnomAD rs1567743212
- V34G (p.Val34Gly), TOPMed rs1567743212, gnomAD rs1567743212
- V35A (p.Val35Ala), Ensembl rs2073451263, REVEL 0.05, CADD 2.23
- V35I (p.Val35Ile), ExAC rs750112543, TOPMed rs750112543, gnomAD rs750112543, REVEL 0.08, CADD 0.03
- P36L (p.Pro36Leu), ESP rs371938974, ExAC rs371938974, TOPMed rs371938974, gnomAD rs371938974, REVEL 0.30, CADD 23.10
- K38E (p.Lys38Glu), rs398124629, ClinGen CA224420, ClinVar RCV000082872, TOPMed rs398124629, REVEL 0.42, CADD 23.20, Likely pathogenic, not provided
- T39H (p.Thr39His), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- T39I (p.Thr39Ile), gnomAD rs1257439172, REVEL 0.11, CADD 0.43
- T39R (p.Thr39Arg), NCI-TCGA Cosmic COSV9923, Variant assessed as somatic; moderate impact.
- Y41C (p.Tyr41Cys), rs1350176353, ClinGen CA400683903, ClinVar RCV004417844, TOPMed rs1350176353, REVEL 0.50, CADD 25.30, Uncertain significance, not specified
- P43A (p.Pro43Ala), NCI-TCGA Cosmic COSV9923, Variant assessed as somatic; moderate impact.
- G44E (p.Gly44Glu), TOPMed rs2073451099
- G44R (p.Gly44Arg), Ensembl rs2073451118
- E45* (p.Glu45Ter), NCI-TCGA Cosmic COSV5277, Variant assessed as somatic; high impact.
- E45D (p.Glu45Asp), ExAC rs760724527, gnomAD rs760724527, REVEL 0.10, CADD 13.30
- E46D (p.Glu46Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E46K (p.Glu46Lys), NCI-TCGA TCGA novel, TOPMed rs2073451042, Variant assessed as somatic; moderate impact.
- E46V (p.Glu46Val), gnomAD rs1314485191, REVEL 0.21, CADD 21.50
- I47N (p.Ile47Asn), TOPMed rs1233203452, gnomAD rs1233203452, REVEL 0.64, CADD 25.20
- I47T (p.Ile47Thr), TOPMed rs1233203452, gnomAD rs1233203452, REVEL 0.53, CADD 23.30
- T48M (p.Thr48Met), TOPMed rs1394413014, gnomAD rs1394413014, REVEL 0.24, CADD 6.44
- T48R (p.Thr48Arg), TOPMed rs1394413014, gnomAD rs1394413014, REVEL 0.29, CADD 7.76
- S50F (p.Ser50Phe), ExAC rs771138077, gnomAD rs771138077, REVEL 0.20, CADD 9.00
- S50Y (p.Ser50Tyr), ExAC rs771138077, gnomAD rs771138077, REVEL 0.23, CADD 14.10
- C51F (p.Cys51Phe), gnomAD rs1166600072, REVEL 0.93, CADD 24.60
- C51R (p.Cys51Arg), gnomAD rs1369724960, REVEL 0.93, CADD 25.60
- K52N (p.Lys52Asn), TOPMed rs1017001765, gnomAD rs1017001765, REVEL 0.12, CADD 17.50
- P53L (p.Pro53Leu), ESP rs371962881, ExAC rs371962881, TOPMed rs371962881, gnomAD rs371962881, REVEL 0.43, CADD 24.30
- G54C (p.Gly54Cys), TOPMed rs2073450718, gnomAD rs2073450718, REVEL 0.75, CADD 24.70
- G54V (p.Gly54Val), TOPMed rs1421617583, gnomAD rs1421617583
- Y55C (p.Tyr55Cys), rs748283658, NCI-TCGA Cosmic COSV9923, ExAC rs748283658, TOPMed rs748283658, REVEL 0.50, CADD 25.10, Variant assessed as somatic; moderate impact.
- V56M (p.Val56Met), TOPMed rs1025512314, gnomAD rs1025512314, REVEL 0.07, CADD 0.44
- R58* (p.Arg58Ter), rs150681833, NCI-TCGA Cosmic COSV5277, ESP rs150681833, ExAC rs150681833, CADD 33.00, Variant assessed as somatic; high impact.
- R58G (p.Arg58Gly), ESP rs150681833, ExAC rs150681833, TOPMed rs150681833, gnomAD rs150681833, REVEL 0.41, CADD 18.10
- R58P (p.Arg58Pro), ExAC rs768884547, TOPMed rs768884547, gnomAD rs768884547, REVEL 0.36, CADD 22.00
- R58Q (p.Arg58Gln), NCI-TCGA Cosmic COSV5277, ExAC rs768884547, TOPMed rs768884547, gnomAD rs768884547, REVEL 0.15, CADD 11.90, Variant assessed as somatic; moderate impact.
- G59E (p.Gly59Glu), Ensembl rs867494885
- G60E (p.Gly60Glu), ExAC rs780503271, gnomAD rs780503271, REVEL 0.12, CADD 15.10
- G60R (p.Gly60Arg), ExAC rs747560976, TOPMed rs747560976, gnomAD rs747560976, NCI-TCGA TCGA novel, REVEL 0.14, CADD 21.40, Variant assessed as somatic; moderate impact.
- M61I (p.Met61Ile), ExAC rs745434491, TOPMed rs745434491, gnomAD rs745434491
- R62K (p.Arg62Lys), ExAC rs778366478, TOPMed rs778366478, gnomAD rs778366478, REVEL 0.32, CADD 16.60
- K63E (p.Lys63Glu), ExAC rs769462036, TOPMed rs769462036, gnomAD rs769462036, REVEL 0.20, CADD 13.10
- K63Q (p.Lys63Gln), ExAC rs769462036, TOPMed rs769462036, gnomAD rs769462036
- K63R (p.Lys63Arg), Ensembl rs747763235
- F64C (p.Phe64Cys), ESP rs368674146, ExAC rs368674146, TOPMed rs368674146, gnomAD rs368674146, REVEL 0.40, CADD 23.90
- I65N (p.Ile65Asn), ExAC rs763963470, TOPMed rs763963470, gnomAD rs763963470, REVEL 0.21, CADD 14.40
- I65T (p.Ile65Thr), ExAC rs763963470, TOPMed rs763963470, gnomAD rs763963470
- P67L (p.Pro67Leu), 1000Genomes rs567530022, TOPMed rs567530022, gnomAD rs567530022, REVEL 0.25, CADD 18.60
- P67R (p.Pro67Arg), rs567530022, 1000Genomes rs567530022, TOPMed rs567530022, gnomAD rs567530022, REVEL 0.39, CADD 22.70, Variant assessed as somatic; moderate impact.
- G70A (p.Gly70Ala), gnomAD rs937249568, REVEL 0.51, CADD 23.20
- L71M (p.Leu71Met), TOPMed rs780689357, gnomAD rs780689357, REVEL 0.09, CADD 0.00
- W72G (p.Trp72Gly), gnomAD rs1162651949
- P73H (p.Pro73His), TOPMed rs2073450217, gnomAD rs2073450217
- P73L (p.Pro73Leu), TOPMed rs2073450217, gnomAD rs2073450217, REVEL 0.32, CADD 25.20
- P73S (p.Pro73Ser), TOPMed rs1455885466, gnomAD rs1455885466
- I74V (p.Ile74Val), TOPMed rs1369699001, gnomAD rs1369699001, REVEL 0.03, CADD 0.54
- N75D (p.Asn75Asp), ExAC rs752710676, gnomAD rs752710676, REVEL 0.12, CADD 23.60
- N75S (p.Asn75Ser), rs138225887, ClinGen CA8720492, ClinVar RCV000950824, 1000Genomes rs138225887, REVEL 0.10, CADD 20.50, Benign, not provided
- T76S (p.Thr76Ser), TOPMed rs1299775897, gnomAD rs1299775897, REVEL 0.07, CADD 17.90
- L77P (p.Leu77Pro), TOPMed rs1368050083, REVEL 0.22, CADD 24.60
- L77V (p.Leu77Val), ExAC rs1803124, gnomAD rs1803124, REVEL 0.08, CADD 18.20
- K78E (p.Lys78Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K78N (p.Lys78Asn), TOPMed rs1229578006
- C79S (p.Cys79Ser), TOPMed rs1483624277, gnomAD rs1483624277, REVEL 0.86, CADD 25.10
- C79Y (p.Cys79Tyr), TOPMed rs1483624277, gnomAD rs1483624277, Uncertain significance, not specified
- T80I (p.Thr80Ile), Ensembl rs2147000327
- P81H (p.Pro81His), rs373786395, ClinGen CA8720461, ClinVar RCV004182443, ESP rs373786395, REVEL 0.64, CADD 27.80, Uncertain significance, not specified
- P81L (p.Pro81Leu), ESP rs373786395, ExAC rs373786395, TOPMed rs373786395, gnomAD rs373786395, REVEL 0.60, CADD 31.00, Uncertain significance
- P81S (p.Pro81Ser), rs762150092, ExAC rs762150092, TOPMed rs762150092, gnomAD rs762150092, REVEL 0.48, CADD 24.40, Variant assessed as somatic; moderate impact.
- R82K (p.Arg82Lys), gnomAD rs1322059210, REVEL 0.17, CADD 16.40
- V83I (p.Val83Ile), ExAC rs760052531, TOPMed rs760052531, gnomAD rs760052531
- C84R (p.Cys84Arg), TOPMed rs1430551583, REVEL 0.88, CADD 29.20
- P85S (p.Pro85Ser), rs55645281, NCI-TCGA Cosmic COSV5277, gnomAD rs55645281, AlphaMissense 0.15, MetaLR 0.28, Variant assessed as somatic; moderate impact.
- P85T (p.Pro85Thr), rs55645281, NCI-TCGA Cosmic COSV5277, gnomAD rs55645281, AlphaMissense 0.15, MetaLR 0.28, Variant assessed as somatic; moderate impact.
- F86L (p.Phe86Leu), ExAC rs777314989, gnomAD rs777314989, REVEL 0.20, CADD 23.10
- F86S (p.Phe86Ser), rs2511980794, ClinGen CA400683617, ClinVar RCV004277542, REVEL 0.25, CADD 23.80, Uncertain significance, not specified
- L90S (p.Leu90Ser), rs1189396256, NCI-TCGA Cosmic COSV9923, gnomAD rs1189396256, REVEL 0.59, CADD 28.50, Variant assessed as somatic; moderate impact.
- E91G (p.Glu91Gly), 1000Genomes rs12544, ExAC rs12544, TOPMed rs12544, gnomAD rs12544, REVEL 0.39, CADD 25.00
- E91K (p.Glu91Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E91Q (p.Glu91Gln), ExAC rs769370693, gnomAD rs769370693, REVEL 0.08, CADD 19.90
- N92D (p.Asn92Asp), Ensembl rs753680863, REVEL 0.28, CADD 26.30
- G93E (p.Gly93Glu), rs138448367, ESP rs138448367, ExAC rs138448367, TOPMed rs138448367, REVEL 0.61, CADD 26.40, Variant assessed as somatic; moderate impact.
- A94T (p.Ala94Thr), TOPMed rs2073437672
- V95A (p.Val95Ala), TOPMed rs1567742413, REVEL 0.20, CADD 26.10
- V95I (p.Val95Ile), 1000Genomes rs55729748, ExAC rs55729748, TOPMed rs55729748, gnomAD rs55729748, REVEL 0.09, CADD 19.70
- R96C (p.Arg96Cys), rs142075038, ESP rs142075038, ExAC rs142075038, gnomAD rs142075038, REVEL 0.25, CADD 29.50, Variant assessed as somatic; moderate impact.
- R96H (p.Arg96His), rs138847585, ESP rs138847585, ExAC rs138847585, gnomAD rs138847585, REVEL 0.07, CADD 22.70, Variant assessed as somatic; moderate impact.
- R96L (p.Arg96Leu), ESP rs138847585, ExAC rs138847585, gnomAD rs138847585, REVEL 0.17, CADD 23.00
- Y97C (p.Tyr97Cys), ExAC rs764232368, gnomAD rs764232368, REVEL 0.23, CADD 26.10
- Y97F (p.Tyr97Phe), ExAC rs764232368, gnomAD rs764232368, REVEL 0.09, CADD 19.90
- Y97H (p.Tyr97His), TOPMed rs113600096, gnomAD rs113600096, REVEL 0.31, CADD 27.60
- T98K (p.Thr98Lys), ESP rs375933687, ExAC rs375933687, TOPMed rs375933687, gnomAD rs375933687, REVEL 0.23, CADD 24.10
- T98M (p.Thr98Met), ESP rs375933687, ExAC rs375933687, TOPMed rs375933687, gnomAD rs375933687, REVEL 0.32, CADD 27.10
- T98R (p.Thr98Arg), ESP rs375933687, ExAC rs375933687, TOPMed rs375933687, gnomAD rs375933687, REVEL 0.21, CADD 23.00
- T99A (p.Thr99Ala), ExAC rs767873103, TOPMed rs767873103, gnomAD rs767873103, REVEL 0.08, CADD 22.00
- T99S (p.Thr99Ser), ExAC rs767873103, TOPMed rs767873103, gnomAD rs767873103, REVEL 0.08, CADD 19.30
- F100S (p.Phe100Ser), TOPMed rs894371590, REVEL 0.71, CADD 25.60
- E101* (p.Glu101Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- P103R (p.Pro103Arg), Ensembl rs1567742385, REVEL 0.32, CADD 22.40
- N104D (p.Asn104Asp), ExAC rs774860125, TOPMed rs774860125, gnomAD rs774860125, REVEL 0.22, CADD 24.20
- N104S (p.Asn104Ser), ExAC rs771390376, gnomAD rs771390376, REVEL 0.13, CADD 18.20
- T105K (p.Thr105Lys), rs373470263, ClinGen CA400683502, ClinVar RCV004100777, AlphaMissense 0.08, MetaLR 0.33, Uncertain significance, not specified
- T105M (p.Thr105Met), ESP rs373470263, ExAC rs373470263, TOPMed rs373470263, gnomAD rs373470263, REVEL 0.20, AlphaMissense 0.08
- S107N (p.Ser107Asn), rs1801692, UniProt VAR 008169, 1000Genomes rs1801692, ESP rs1801692, REVEL 0.05, CADD 5.89, Benign, in allele APOH*1
- S107R (p.Ser107Arg), TOPMed rs1567742374, gnomAD rs1567742374, REVEL 0.25, CADD 17.20
- F108L (p.Phe108Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- F108V (p.Phe108Val), gnomAD rs1258002112, REVEL 0.53, CADD 26.20
- S109F (p.Ser109Phe), gnomAD rs1339937905, REVEL 0.40, CADD 26.20
- S109P (p.Ser109Pro), ExAC rs780921032, TOPMed rs780921032, gnomAD rs780921032
- C110F (p.Cys110Phe), ExAC rs779872282, TOPMed rs779872282, gnomAD rs779872282
- C110R (p.Cys110Arg), 1000Genomes rs558145665, ExAC rs558145665, gnomAD rs558145665, REVEL 0.87, CADD 27.00
- C110W (p.Cys110Trp), Ensembl rs1567742362
- C110Y (p.Cys110Tyr), rs779872282, ExAC rs779872282, TOPMed rs779872282, gnomAD rs779872282, REVEL 0.90, CADD 25.90, Variant assessed as somatic; moderate impact.
- G113E (p.Gly113Glu), TOPMed rs1449823168, gnomAD rs1449823168, REVEL 0.78, CADD 33.00
- G113R (p.Gly113Arg), Ensembl rs2073437099, REVEL 0.72, CADD 25.10
- Y115H (p.Tyr115His), rs756210824, ExAC rs756210824, TOPMed rs756210824, gnomAD rs756210824, REVEL 0.12, CADD 17.10, Variant assessed as somatic; moderate impact.
- Y115S (p.Tyr115Ser), ExAC rs748274839, gnomAD rs748274839, REVEL 0.24, CADD 15.30
- G118D (p.Gly118Asp), TOPMed rs940464523, REVEL 0.74, CADD 24.40
- A119D (p.Ala119Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A119T (p.Ala119Thr), rs189980938, ClinGen CA8720406, ClinVar RCV004304331, 1000Genomes rs189980938, REVEL 0.03, CADD 1.21, Likely benign, not specified
- S121P (p.Ser121Pro), ExAC rs751793235, gnomAD rs751793235, REVEL 0.33, CADD 20.20
- A122P (p.Ala122Pro), Ensembl rs2073417771, REVEL 0.41, CADD 21.60
- A122V (p.Ala122Val), Ensembl rs971002465
- K123R (p.Lys123Arg), ExAC rs766663087, TOPMed rs766663087, gnomAD rs766663087, REVEL 0.04, CADD 5.40
- C124G (p.Cys124Gly), ExAC rs552047225, TOPMed rs552047225, REVEL 0.83, CADD 25.00
- C124R (p.Cys124Arg), ExAC rs552047225, TOPMed rs552047225, REVEL 0.83, CADD 24.90
- C124S (p.Cys124Ser), ExAC rs552047225, TOPMed rs552047225, REVEL 0.85, CADD 24.30
- T125A (p.Thr125Ala), TOPMed rs2073417583, REVEL 0.29, CADD 18.60
- T125I (p.Thr125Ile), rs1267030670, ClinGen CA400682910, ClinVar RCV004321690, TOPMed rs1267030670, REVEL 0.20, CADD 19.70, Uncertain significance, not specified
- E127K (p.Glu127Lys), gnomAD rs1331617940
- G128* (p.Gly128Ter), TOPMed rs867737026, CADD 38.00
- G128E (p.Gly128Glu), NCI-TCGA Cosmic COSV5277, REVEL 0.65, CADD 24.30, Variant assessed as somatic; moderate impact.
- K129R (p.Lys129Arg), TOPMed rs1360166805, gnomAD rs1360166805, REVEL 0.04, CADD 2.28
- W130C (p.Trp130Cys), gnomAD rs1219058843, REVEL 0.73, CADD 25.80
- W130G (p.Trp130Gly), ExAC rs776349608, TOPMed rs776349608, gnomAD rs776349608, REVEL 0.76, CADD 28.70
- W130R (p.Trp130Arg), NCI-TCGA Cosmic COSV5277, Variant assessed as somatic; moderate impact.
- S131I (p.Ser131Ile), TOPMed rs2073417323, REVEL 0.40, CADD 15.60
- S131N (p.Ser131Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P132L (p.Pro132Leu), rs763687723, ExAC rs763687723, TOPMed rs763687723, gnomAD rs763687723, REVEL 0.08, CADD 2.89, Variant assessed as somatic; moderate impact.
- E133K (p.Glu133Lys), ExAC rs775142630, TOPMed rs775142630, gnomAD rs775142630, REVEL 0.24, CADD 1.25
- L134P (p.Leu134Pro), gnomAD rs112676310, REVEL 0.35, CADD 15.20
- P135S (p.Pro135Ser), rs1567740983, NCI-TCGA Cosmic COSV5277, Ensembl rs1567740983, AlphaMissense 0.63, MetaLR 0.75, Variant assessed as somatic; moderate impact.
- V136F (p.Val136Phe), gnomAD rs1318742692, REVEL 0.36, CADD 24.00
- P139A (p.Pro139Ala), rs141252899, ESP rs141252899, ExAC rs141252899, TOPMed rs141252899, REVEL 0.04, CADD 18.10, Variant assessed as somatic; moderate impact.
- P139L (p.Pro139Leu), TOPMed rs1261928380, gnomAD rs1261928380
- P139R (p.Pro139Arg), TOPMed rs1261928380, gnomAD rs1261928380
- P139S (p.Pro139Ser), ESP rs141252899, ExAC rs141252899, TOPMed rs141252899, gnomAD rs141252899, REVEL 0.07, CADD 20.40
Public APOH analysis runs
- APOH analysis run — APOH (680 variants) — completed 2026-08-22